Compare Incyte Corporation (INCY) vs Nano Dimension Ltd - ADR (NNDM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Nano Dimension Ltd - ADR — how do they compare? Incyte Corporation trades at $121.06 (market cap $24.54B), while Nano Dimension Ltd - ADR trades at $1.65 (market cap $350.49M). The key difference: Incyte Corporation is far larger — about 70× Nano Dimension Ltd - ADR's market cap, and Incyte Corporation is trading nearer its 52-week high, Nano Dimension Ltd - ADR nearer its low. Which is the better fit depends on your goals.
| INCY | NNDM | |
|---|---|---|
Market Cap | $24.54B | $350.49M |
Sector | Health | Technology |
52-Week High | $129.93 | $2.14 |
52-Week Low | $81.61 | $1.21 |
Enterprise Value | $20.04B | -$54.35M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
NNDM trades at $1.655, up 1.53% today, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of -$0.03, beating expectations, while revenue grew to $102.44M in 2025. However, net income remains deeply negative at -$293.30M, and cash flow from operations is negative. Recent strategic moves include selling MarkForged to Stratasys and cost-saving initiatives to reduce cash burn.
Outlook: Potential upside from strategic divestitures and cost cuts, but high execution risk and persistent losses pose significant challenges. Investors should weigh the low P/B of 0.73 against sustained profitability concerns and shareholder disputes highlighted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Nano Dimension Ltd - ADR
Nano Dimension Ltd is engaged in research and development of a three-dimensional printer that prints electronic circuit boards, also known as printed circuit boards, and ink materials and products based on nanotechnology. Its products consist of two main product lines - Dragonfly 2020 3D printer and proprietary ink products. The company's Dragonfly 2020 3D printer currently in development uses proprietary ink and integrated software to quickly create fully functioning PCB prototypes. Geographically, it generates maximum revenue from the USA followed by the Asia Pacific and Europe and Israel. It serves the Commercial, Research and Printing services industries.
Read more on NNDM →
